AMA supports physicians who prescribe hydroxychloroquine, HCQ for treatment of Covid-19

I do not think most people understand that by October 2020 the American Medical Association had rescinded "its statement calling for physicians to stop prescribing hydroxychloroquine and chloroquine" from March of 2020, and supports "a physician’s ability to prescribe an FDA-approved medication for off label use."

It is all documented on the AMA web site, though somewhat buried in group of Resolutions announced in a memorandum released Oct. 30, 2020.

Whereas, The original studies published in The Lancet and The New England Journal of Medicine (NEJM) initially citing harm due to hydroxychloroquine and chloroquine use were retracted by said journals due to dubious research methodology and incorrect conclusions...
RESOLVED, That our American Medical Association rescind its statement calling for physicians to stop prescribing hydroxychloroquine and chloroquine until sufficient evidence becomes available to conclusively illustrate that the harm associated with use outweighs benefit early in the disease course. Implying that such treatment is inappropriate contradicts AMA Policy H-120.988, “Patient Access to Treatments Prescribed by Their Physicians,” that addresses off label prescriptions as appropriate in the judgement of the prescribing physician (Directive to Take Action);

RESOLVED, That our AMA reassure the patients whose physicians are prescribing hydroxychloroquine and combination therapies for their early-stage COVID-19 diagnosis by issuing an updated statement clarifying our support for a physician’s ability to prescribe an FDA-approved medication for off label use, if it is in her/his best clinical judgement, with specific reference to the use of hydroxychloroquine and combination therapies for the treatment of the earliest stage of COVID-19 (Directive to Take Action); and be it further RESOLVED, That our AMA take the actions necessary to require local pharmacies to fill valid prescriptions that are issued by physicians and consistent with AMA principles articulated in AMA Policy H-120.988, “Patient Access to Treatments Prescribed by Their Physicians,” including working with the American Pharmacists Association and American Society of Health System Pharmacists. (Directive to Take Action)